Sector News

Merck & Co rumoured to be in talks to buy Cubist

December 8, 2014
Life sciences
Merck & Co is rumoured to be in talks to acquire Cubist Pharmaceuticals with a price of $7-$8 billion being mentioned for the antibiotics specialist.
 
Reports of a deal surfaced in the New York Times, prompting a 26% leap in after-hours trading for Cubist stock to $93.50. The companies are not commenting on the rumours but the newspaper cited unnamed sources as saying Merck could pay $100 a share, valuing Cubist at about $7.5 billion; a deal could be announced as early as this week, the NYT claims.
 
Cubist posted revenues of $864.8 million in the first nine months of 2014, most of which came from the antibacterial Cubicin (daptomycin). In June, the US Food and Drug Administration approved Cubist’s Sivextro (tedizolid) for serious skin infections.
 
A tie-up with Cubist, which is regularly mentioned as a takeover target, would make sense for Merck which recently saw its antibiotic relebactam fast-tracked by the FDA.
 
By Kevin Grogan
 
Source: Pharma Times

comments closed

Related News

December 3, 2023

FDA names chief scientist Bumpus as Woodcock’s successor

Life sciences

The Food and Drug Administration’s top scientist Namandjé Bumpus will assume the role of principal deputy commissioner when longtime agency leader Janet Woodcock retires from that role in early 2024, according to an announcement Thursday.

December 3, 2023

AbbVie to buy cancer drug maker ImmunoGen for $10.1 Billion

Life sciences

US biopharma AbbVie has agreed to acquire ImmunoGen in a deal which values the company at about $10.1 billion and gives AbbVie access to flagship cancer therapy Elahere (mirvetuximab soravtansine-gynx), a first-in-class antibody-drug conjugate (ADC) approved for platinum-resistant ovarian cancer (PROC), as well as a pipeline of promising next-generation ADCs.

December 3, 2023

EuroAPI appoints new Executive Committee members

Life sciences

EUROAPI today announced the appointment of David Seignolle as Chief Operating Officer, succeeding Eric Berger, and Marion Santin as Chief Legal, Compliance, and IP Officer, both joining the company’s Executive Committee. In his new role, David Seignolle will lead the transformation of the Industrial Operations organization.

How can we help you?

We're easy to reach